Moderna Stock News

Moderna may have a number of new product launches ahead. Pfizer is a big pharma stock that's poised for a big comeback.

Major U.S. equities indexes headed higher after the latest Producer Price Index (PPI) report showed a cooldown in wholesale inflation in August, the latest data point that could tip the scales toward an interest-rate cut when the Federal Reserve meets next week.

Shares of Moderna Inc (NASDAQ:MRNA) are plummeting today, after the biotech giant announced it was slashing its research budget by about 20%.

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

US pharmaceuticals giant Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares tanked more than 17% on Thursday after announcing a $1.2 billion cost-cutting plan in its research and development department. Moderna successfully commercialised its Covid-19 vaccine at the height of the pandemic leading to an all-time high valuation in September 2021.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292...

Moderna Inc. (NASDAQ: MRNA) saw its stock plunge more than 14% on Thursday, following the company's announcement of significant cuts to its annual research and development (R&D) expenses. The biotech giant revealed plans to slash its R&D budget by $1.1 billion starting in 2027, reducing annual expenditure from $4.8 billion in 2024 to between $3.

Moderna (MRNA) shares tumbled in pre-market trading Thursday as the company said it plans to cut costs and suspend or end development of some products as it focuses on later-stage trials.